Caris & Company Downgrades AngioDynamics (ANGO) to Above Average
More News related to ANGO
- AngioDynamics to Participate in the 21st Annual Piper Jaffray Health Care Conference
- AngioDynamics Appoints Stephen McGill as Senior Vice President and General Manager, International
- AngioDynamics (ANGO) Tops Q1 Views; Raises FY10 Outlook
- AngioDynamics Reports Fiscal First Quarter 2010 Financial Results
- Trading Radar for 10/06: Yum! (YUM), Pepsi Bottling (PBG), Chattem (CHTT), AngioDynamics (ANGO) Report
Caris & Company downgrades AngioDynamics (Nasdaq: ANGO) from Buy to Above Average and lowers their price target from $20 to $15.
AngioDynamics, Inc. designs, develops, manufactures, and markets various therapeutic and diagnostic devices that enable interventional physicians to treat peripheral vascular disease, tumors, and other non-coronary diseases.
Related Categories
DowngradesStocks Mentioned
-0.25Related Entities
Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
ka
max on Mar 10, 2009 03:26 PMka